Search
Phenylbutazone
go.drugbank.com/drugs/DB00812ApprovedVet approvedWithdrawnAlthough phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822)
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UseTrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082ApprovedTrenibotulinumtoxinE is a botulinum neurotoxin serotype E, produced in *Clostridium botulinum*, used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. … [L64095,L64118] It is given as an intramuscular injection into the corrugator and procerus muscles, is intended for occasional use, and its potency units are not interchangeable with those of other botulinum
Ethynodiol diacetate
go.drugbank.com/drugs/DB00823ApprovedAlthough etynodiol or ethynodiol are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug
Categories: Hormonal Contraceptives for Systemic UseTideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnTideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … A262601] Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for
Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240254, A240259, A240264, A240269] Avacopan (formerly CCX168) is an allosteric C5aR antagonist indicated for use in AAV. … [L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]
Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnIt is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalApproval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. … Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Nitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalThere is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections.